Nov 5, 2021 · XmAb18968 is structurally distinct CD3-CD38 bi-specific T-cell engager with a full fragment crystallizable (Fc) domain modified to minimize Fcγ receptor binding and non-selective activation of T cells and other immune effector cells.

Sep 11, 2024 · Despite recent advances in immunotherapies targeting single tumor-associated antigens, patients with multiple myeloma eventually relapse. ISB 2001 is a CD3 + T cell engager (TCE) co-targeting...

CD38 is a multifunctional membrane surface glycoprotein expressed by different cells and tissues, including T cells at certain stages of their development. Besides its involvement in transmembrane signaling, CD38 play a role in cell adhesion processes.

Here, we developed a trispecific antibody that interacts with CD38, CD3 and CD28 to enhance both T cell activation and tumor targeting. The engagement of both CD3 and CD28 affords efficient T cell stimulation, whereas the anti-CD38 domain directs T cells to myeloma cells, as well as to certain lymphomas and leukemias.

We have developed a new BiTE (Bi38-3) that consists of two single-chain variable fragments derived from mouse hybridomas, producing anti-human CD38 and CD3e (Online Supplementary Figure S1A and B).

Jul 24, 2024 · Targeting CD38 with isatuximab and a CD38/CD3 × CD28 trispecific T-cell engager (CD38-TCE). The KG-1 as well as the MOLM-13 and OCI-AML3 AML cell lines were selected because of their respective low and bright density of CD38.

Jun 19, 2024 · In this study, anti-CD38 targeted therapy rapidly boosted platelet levels by inhibiting antibody-dependent cell-mediated cytotoxicity on platelets, maintained long-term efficacy by clearing...

CD38 mediated regulation of metabolic pathways and chromatin modifications in T cells. CD38 affects the differentiation and effector response of T cells through modulating the metabolic pathways and epigenetic landscape of T cells.

In vitro and preclinical results show that anti-CD3/BCMA/CD38 trispecific antibodies have stronger binding affinity and killing potency compared to daratumumab, isatuximab, and teclistamab antibodies.

Aug 17, 2021 · Currently, there are three CD38/CD3-targeting BiTEs to treat MM – all of which are in phase I clinical trials. It was recently shown that an anti-CD38 bispecific antibody, AMG424, was able to...